Abstract 1384: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer
Year: 2015
Type: conference-abstract
Source: Cancer Research
Authors: Sarah J. Conley, Trenton L. Baker, Joseph P. Burnet, Rebecca L. Thiesen, Douglas Lazarus, Christian G. Peters, Shawn G. Clouthier, Scott Eliasof, Max S. Wicha
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2532809345